Polymer-Extended Anion Exchange for AAV Capsid Separation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for separating fully packaged adeno-associated virus (AAV) capsids from not fully packaged capsids are inefficient and not scalable, leading to challenges in achieving high purity and therapeutic efficacy due to the diversity of capsids, small differences in isoelectric points, and co-elution of partially packaged capsids.
Innovation Solution
A method using strong anion exchange chromatography with a polymer surface extender, such as polysaccharides or polyvinyl alcohol, to separate fully packaged AAV capsids from not fully packaged capsids, achieving a ratio of at least 3:2 fully packaged to not fully packaged capsids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional chromatography methods are used to separate fully packaged AAV capsids from not fully packaged capsids, then separation is attempted, but the resolution is insufficient due to small differences in isoelectric points, resulting in co-elution of partially packaged capsids
Solution Approach 1:
The patent changes the chemical parameters of the chromatography material by introducing a polymer surface extender (such as polyvinyl alcohol, polysaccharides, or polyacrylamide) with a specific charge density and hydrodynamic volume. This modifies the interaction between the chromatography material and AAV capsids, enhancing the separation resolution based on subtle differences in isoelectric points and surface properties of fully versus partially packaged capsids.
Solution Approach 2:
The patent employs a composite chromatography material consisting of a support structure combined with a polymer surface extender layer. This composite structure provides both mechanical stability and enhanced separation functionality, allowing differential binding of fully packaged and not fully packaged capsids through the polymer layer's specific physicochemical properties.
2Manufacturing precision
If multiple filtration and chromatography steps are used to purify AAV particles, then purity is improved, but the process complexity and production cost increase
Solution Approach 1:
The patent designs a universal chromatography material with a polymer surface extender that can effectively separate fully packaged AAV capsids from not fully packaged capsids across different AAV serotypes. This single material performs multiple functions: it provides high-resolution separation, handles diverse capsid types, and eliminates the need for extensive optimization for each serotype, thereby reducing overall process complexity.
3Manufacturing precision
If ultracentrifugation is used to separate AAV particles, then separation efficiency is high, but scalability is limited
Solution Approach 1:
The patent replaces the mechanical ultracentrifugation system with a chromatography-based separation system. This substitution maintains high separation efficiency through specific molecular interactions between the polymer surface extender and AAV capsids, while enabling scalable continuous processing that is more suitable for large-scale production.
4Manufacturing precision
If extensive optimization is performed for each AAV serotype or variant, then separation effectiveness is improved, but the time and resource cost increase
Solution Approach 1:
The patent creates a universal chromatography material that effectively separates fully packaged capsids across multiple AAV serotypes and variants without requiring extensive serotype-specific optimization. The polymer surface extender's properties provide broad-spectrum applicability, significantly reducing development time and resources while maintaining high separation effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides improved resolution and scalability, resulting in a high ratio of fully packaged capsids, enhancing therapeutic efficacy and reducing production costs.
Implementation Method 1
the chromatography material comprises a strong, or partially strong, anion exchange chromatography material comprising a support and a ligand for binding to the adeno-associated virus capsids
Data Source
AI summary
The present disclosure is directed to a method for separating adeno-associated virus capsids fully packaged with genetic material from adeno-associated virus capsids not fully packaged with genetic material, the method comprising the following steps: a) adding a liquid sample comprising adeno-associated virus capsids to a chromatography material, wherein the liquid sample comprises adeno-associated virus capsids of a purity of at least 90% and of a concentration of at least 1012 adeno-associated virus capsids/ml, of which at least 10% of the adeno-associated virus capsids are adeno-associated virus capsids fully packaged with genetic material, wherein the chromatography material comprises a strong, or partially strong, anion exchange chromatography material comprising a support and a ligand for binding to the adeno-associated virus capsids; wherein the chromatography material comprises a surface extender connecting the ligand to the support, wherein the surface extender is a polymer, wherein the polymer is selected from: (i) a polymer having a naturally occurring skeleton, such as a polysaccharide, such as starch, cellulose, dextran, or agarose; and (ii) a polymer having a synthetic skeleton, such as a polyvinyl alcohol, a polyacrylamide, a polymethacrylamide, or a polyvinyl ether; b) eluting the adeno-associated virus capsids fully packaged with genetic material from the chromatography material; wherein the adeno-associated virus capsids eluted in step (b) are eluted into eluate fractions, which eluate fractions combined comprise at least 50% of the adeno-associated virus capsids of the liquid sample added in step (a), of which at least 60% of the adeno-associated virus capsids are fully packaged with genetic material. Further disclosed are compositions, including pharmaceutical compositions, obtained by said separation method, as well as uses of such compositions, and uses of an anion chromatography material for separation of adeno-associated virus capsids.